HopeStage
Back to all studies
CompletedNCT05536414

Centanafadine for depression alone or with an antidepressant

About this titleRead the official source — NCT05536414

This study evaluated the safety and effectiveness of Centanafadine for people with depression.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Centanafadine for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Yuma and 61 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 12, 2022
Recruitment status
Completed
Enrollment listed in the registry
337
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05536414
Official title
Show the full official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Extended-release Capsules as Monotherapy or as Adjunct to SSRI in Adult Subjects With Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Yuma · Bryant · Glendale

53 more locations
  • Lafayette
  • Lancaster
  • Lemon Grove
  • Orange
  • Rancho Cucamonga
  • Redlands
  • San Jose
  • Santa Ana
  • Sherman Oaks
  • Temecula
  • Coral Springs
  • Fort Myers
  • Jacksonville
  • Miami Springs
  • North Miami
  • Orlando
  • Tampa
  • Atlanta
  • Decatur
  • Marietta
  • Peachtree Corners
  • Boise
  • Chicago
  • Elgin
  • Oak Brook
  • Shreveport
  • Baltimore
  • Flowood
  • O'Fallon
  • Toms River
  • Brooklyn
  • New York
  • Rochester
  • Staten Island
  • Cincinnati
  • Garfield Heights
  • North Canton
  • Oklahoma City
  • Portland
  • West Chester
  • Myrtle Beach
  • Memphis
  • Dallas
  • DeSoto
  • Houston
  • Irving
  • Plano
  • Wichita Falls
  • Clinton
  • Draper
  • Bennington
  • Charlottesville
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Centanafadine for people with depression.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Centanafadine, Escitalopram and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies